drugset / Trial / NCT03642964

A Study in Patients With Major Depressive Disorder

NCT03642964

Phase 2 Active not recruiting 24 enrolled Chase Therapeutics Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).

Timeline

Start
2018-09-10
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown Oral
Background Ondansetron Other / unclassified 8 mg Oral